Bronte Capital Management Pty Ltd. Trims Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Bronte Capital Management Pty Ltd. lessened its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.0% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 180,283 shares of the biopharmaceutical company’s stock after selling 7,587 shares during the period. Regeneron Pharmaceuticals accounts for about 13.8% of Bronte Capital Management Pty Ltd.’s portfolio, making the stock its 3rd biggest holding. Bronte Capital Management Pty Ltd. owned about 0.17% of Regeneron Pharmaceuticals worth $101,368,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Brighton Jones LLC raised its holdings in Regeneron Pharmaceuticals by 261.8% in the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock valued at $675,000 after buying an additional 686 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter valued at about $226,000. Ameritas Advisory Services LLC bought a new stake in Regeneron Pharmaceuticals in the second quarter valued at approximately $45,000. Valeo Financial Advisors LLC increased its position in shares of Regeneron Pharmaceuticals by 50.4% during the second quarter. Valeo Financial Advisors LLC now owns 1,787 shares of the biopharmaceutical company’s stock worth $938,000 after buying an additional 599 shares during the period. Finally, Arcataur Capital Management LLC raised its stake in Regeneron Pharmaceuticals by 3.7% during the second quarter. Arcataur Capital Management LLC now owns 1,038 shares of the biopharmaceutical company’s stock worth $545,000 after buying an additional 37 shares during the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock opened at $775.28 on Thursday. The business has a 50-day simple moving average of $757.52 and a 200 day simple moving average of $655.10. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $821.11. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.77 and a quick ratio of 4.22. The firm has a market capitalization of $81.48 billion, a price-to-earnings ratio of 18.65, a PEG ratio of 2.05 and a beta of 0.40.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, beating analysts’ consensus estimates of $10.74 by $0.70. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The firm had revenue of $3.88 billion during the quarter, compared to analysts’ expectations of $3.76 billion. During the same quarter last year, the firm posted $12.07 earnings per share. The company’s revenue for the quarter was up 2.5% compared to the same quarter last year. On average, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 5th. Shareholders of record on Friday, February 20th will be paid a dividend of $0.94 per share. This is a boost from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. The ex-dividend date is Friday, February 20th. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 8.47%.

Analyst Ratings Changes

A number of brokerages have weighed in on REGN. Royal Bank Of Canada increased their price target on Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the stock a “sector perform” rating in a report on Wednesday, October 29th. BMO Capital Markets upped their target price on Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the company an “outperform” rating in a research report on Thursday, December 4th. Evercore ISI raised their target price on Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the stock an “outperform” rating in a research note on Thursday, January 22nd. Oppenheimer reissued an “outperform” rating and issued a $865.00 price target (up from $750.00) on shares of Regeneron Pharmaceuticals in a research note on Monday. Finally, Cantor Fitzgerald increased their price target on Regeneron Pharmaceuticals from $740.00 to $800.00 and gave the stock an “overweight” rating in a report on Monday. Three research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $788.57.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Bonnie L. Bassler sold 1,500 shares of the business’s stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the completion of the sale, the director directly owned 1,703 shares of the company’s stock, valued at $1,362,400. The trade was a 46.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Jason Pitofsky sold 431 shares of the company’s stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $651.43, for a total transaction of $280,766.33. Following the completion of the sale, the vice president owned 4,233 shares in the company, valued at $2,757,503.19. This represents a 9.24% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.